|
In the United States, it takes over $1 billion to develop a new drug, and Indian firms develop drugs for $300 million. Along with lower labor and facility costs, there are far fewer obstacles to carrying out clinical trials in India.
Due to the generosity of the US Govt towards a fellow Democracy, Indians have access to several thousand visas. This loop-hole in the “TECHNOLOGY DIKE OF US, has been fully exploited by Technology thieves from India. Indians have penetrated areas of most cutting-edge technology development. Technology hubs :
According to: John Trumpbour, Research Director, Labor & Worklife Program, Harvard Law School: ” To start with India, leaders of the pharmaceutical industry, specifically Ranbaxy, Dr. Reddy’s Laboratories, and Aurigene, indicated that a majority of the PhDs in drug discovery received their degrees in the USA. With several Big Pharma firms based in the USA slashing scientific jobs in recent years, Indian pharmaceutical firms marvel at the expanding talent pool, and they have been diligently recruiting South Asians with U.S. experience for work in India. The pharmaceutical companies are the highest spenders on R&D across all industry sectors in India. To start with India, leaders of the pharmaceutical industry, specifically Ranbaxy, Dr. Reddy’s Laboratories, and Aurigene, indicated that a majority of the PhDs in drug discovery received their degrees in the USA. With several Big Pharma firms based in the USA slashing scientific jobs in recent years, Indian pharmaceutical firms marvel at the expanding talent pool, and they have been diligently recruiting South Asians with U.S. experience for work in India. The pharmaceutical companies are the highest spenders on R&D across all industry sectors in India.” Thousands of Indians working in the US Pharmaceutical Industry, eventually, return to India taking with them the technologies developed with the US dime. This may be the tip of the iceberg. The Economic Times of India (Ref), published the news about an Indian sentenced to year in prison for stealing trade secrets:
Indian sentenced to year in prison for stealing trade secrets
BOSTON: An Indian ex-employee of Bristol-Myers-Squibb, who admitted stealing trade secrets from the drug manufacturer for his planned business venture in India, was awarded a year in jail today, a sentence he has already served.
Shalin Jhaveri, 30 is expected to be deported to India soon.
US District Judge Norman Mordue sentenced Jhaveri to his time served in a New York jail.
Mordue also imposed a USD 5,000 fine and ordered Jhaveri to forfeit the computer equipment he used to steal the formulas.
Federal immigration agents took Jhaveri into custody and would transport him to a detention centre where he will face deportation proceedings in 10 days.
Jhaveri sobbed in court as he apologised for betraying the trust of the company and his family, the Syracuse Post-Standard reported that
“I have failed in my most significant purpose of being on this earth, and I am ashamed,” Jhaveri said.
Jhaveri had pleaded guilty last year to a one-count charge of theft of trade secrets. He was arrested in February 2010.
A Syracuse, New York resident, Jhaveri worked as a technical operations associate in Bristol-Myers’ management training programme.
He had worked at the company since November 2007 at its Syracuse facility, where it develops and manufactures biotechnology medicines for clinical and commercial use.
While he was employed, Jhaveri stole the company’s trade secrets and devised a plan to put them to his own use.
At the time of his arrest, he was meeting with an investor who was willing to finance Jhaveri’s business venture planned in India.
Jhaveri had taken more than 1,300 documents from the company starting in late 2009.
He downloaded the information to his laptop and portable hard drives over the course of several days and shared these trade secrets with his potential investor.
The trade secrets included formulas for producing a drug under development at Bristol to treat a rare and deadly form of skin cancer.
In December 2009, Bristol-Myers’ corporate security had notified its in-house computer security experts that Jhaveri was taking confidential material.
Jhaveri, who came to the US eight years ago on a student visa, has a doctorate in chemistry from Cornell University.
